Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
HighLife is a medtech company focused on Transcatheter Mitral Valve Replacement (TMVR) for treating mitral regurgitation.
HighLife develops a minimally invasive prosthetic mitral valve implanted on a beating heart through the femoral vein and artery while preserving the native valve structure and respecting the surrounding anatomy.
Recognized as being best-in-class, the valve can be delivered trans-septally via the femoral vein in a reversible manner. The trans-septal route is the preferred route for both interventionists and patients as it avoids any surgery.
One of the few trans-septal valves in clinical development, HighLife competes with large international medtech companies and its technology offers differentiating features, notably: ease of use, self-centering and broad-fitting.
HighLife needed to raise funds to finance a US feasibility study and pivotal CE-marking study until 2021.
HighLife SAS was established in 2010 and is headquartered in Paris, France, with offices in Irvine (California). It is focused on the development of a novel transcatheter replacement system for treating mitral regurgitation. The technology aims at a beating heart procedure reducing trauma to the patients.
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acted as Sole Financial Advisor to HighLife. We conducted a broad, international private placement process targeting specialist and generalist funds across Europe, the US and China.
This €32m series B investment round was led by renowned American & European VC funds: USVP and Andera Partners, together with Sectoral Asset Management and Jose Calle Gordo, the company’s Chairman; Sofinnova, the major shareholder, significantly reinvested as well.
This transaction demonstrates our ability to support management teams throughout a demanding fundraising process and to access relevant investors that are today required to achieve larger size of fundraising.
In 2018 Bryan, Garnier & Co closed 19 transactions involving healthcare growth companies across Europe and the US. In particular we were advisors to Moderna for its pre-IPO round, bookrunners for the Medartis IPO on the SIX Swiss Stock Exchange, advised the sale of TxCell to Sangamo Therapeutics, led the follow-on offering of Celyad on NASDAQ and advised Montagu in its LBO on Maincare.